Stock 688626 XIANGYU MEDICAL CO.,LTD
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Xiangyu Medical Co.,Ltd

Equities

688626

CNE100005394

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-06-04 pm EDT 		5-day change 1st Jan Change
33.69 CNY -1.64% Intraday chart for Xiangyu Medical Co.,Ltd -4.18% -36.78%
Apr. 17 Xiangyu Medical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 02 Tranche Update on Xiangyu Medical Co.,Ltd's Equity Buyback Plan announced on August 10, 2023. CI

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Analyst opinion has improved significantly over the past four months.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

1st Jan change Capi. Investor Rating ESG Refinitiv
XIANGYU MEDICAL CO.,LTD Stock Xiangyu Medical Co.,Ltd
-36.78% 730M -
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+8.38% 220B
B
DANAHER CORPORATION Stock Danaher Corporation
+15.78% 198B
B-
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+31.27% 112B
A-
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
+3.76% 66.17B
A-
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+14.19% 52.47B
B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
+4.70% 50.77B
B+
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-3.93% 38.97B
A
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
-0.47% 35.13B -
RESMED, INC. Stock ResMed, Inc.
+23.96% 31.32B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. 688626 Stock
  4. Ratings Xiangyu Medical Co.,Ltd